

This article was downloaded by:

On: 25 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Design, Enantiopure Synthesis, and Biological Evaluation of Novel ISO-D-2',3'-Dideoxy-3'-Fluorothianucleoside Derivatives as a bioisostere of Lamivudine

Kyung Ran Kim^a; Ah-Young Park^a; Hyung Ryong Moon^a; Moon Woo Chun^b; Lak Shin Jeong^c

^a College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Korea ^b College of Pharmacy, Seoul National University, Seoul, Korea ^c College of Pharmacy, Ewha Womans University, Seoul, Korea

To cite this Article Kim, Kyung Ran , Park, Ah-Young , Moon, Hyung Ryong , Chun, Moon Woo and Jeong, Lak Shin(2007) 'Design, Enantiopure Synthesis, and Biological Evaluation of Novel ISO-D-2',3'-Dideoxy-3'-Fluorothianucleoside Derivatives as a bioisostere of Lamivudine', *Nucleosides, Nucleotides and Nucleic Acids*, 26: 8, 911 — 915

To link to this Article: DOI: 10.1080/15257770701506426

URL: <http://dx.doi.org/10.1080/15257770701506426>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

DESIGN, ENANTIOPURE SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL ISO-D-2',3'-DIDEOXY-3'-FLUOROTHIANUCLEOSIDE DERIVATIVES AS A BIOISOSTERE OF LAMIVUDINE

Kyung Ran Kim, Ah-Young Park, and Hyung Ryong Moon □ *College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Korea*

Moon Woo Chun □ *College of Pharmacy, Seoul National University, Seoul, Korea*

Lak Shin Jeong □ *College of Pharmacy, Ewha Womans University, Seoul, Korea*

□ *Novel iso D-2',3'-dideoxythianucleoside derivatives 1–3 were designed and asymmetrically synthesized to search for new anti-HIV agents. Final compounds 1–3 were evaluated against a variety of viruses including HIV-1 and 2. Only cytosine analog 3 showed a potent anti-VSV activity ($EC_{50} = 9.43 \mu\text{g/mL}$). This result implies that iso 2',3'-dideoxy sugar templates might play a role of a sugar surrogate of nucleosides for the development of anti-RNA virus agent.*

Keywords Anti-HIV agents; 2'-3'-dideoxy sugar templates; anti-VSV activity; sulfur participation

INTRODUCTION

Although 2',3'-ddNs (2',3'-dideoxynucleosides) such as zidovudine,^[1] didanosine,^[2] zalcitabine,^[3] and stavudine^[4] have been launched as drugs for the treatment of AIDS patients, these nucleosides have several drawbacks such as easy cleavage of their glycosidic bond under acidic conditions similar to a gastric environment and catabolism by several enzymes. Lamivudine (3TC)^[5] also has been clinically used for the treatment of AIDS and HBV (hepatitis B virus) infection. Structural characteristics of lamivudine are that there is no hydroxyl substituent at both its 2'- and 3'-positions

Kyung Ran Kim and Ah-Young Park contributed equally to this article.

This work was supported for two years by Pusan National University Research Grant (to H. R. Moon).

Address correspondence to Hyung Ryong Moon, College of Pharmacy and Research Institute for Drug Development, Pusan National University, San 30 Jangjeon-dong, Geumjeong-gu, Busan 609-735, Korea. E-mail: mhr108@pusan.ac.kr





FIGURE 1 The rationale for the design of the desired nucleosides 1–3.


like 2',3'-ddN analogues and are two heteroatoms on the ring of its sugar moiety. In addition, lamivudine belongs to L-nucleoside unlike other anti-AIDS drugs. Isonucleosides^[6] in which their base is moved into C2' position from anomeric position have been synthesized and among them, iso-ddA and iso-ddG were found to be active against HIV-1 (Figure 1). Isonucleosides were known to possess the intrinsic metabolic advantages such as resistance to ADA and enhanced stability of glycosidic bond under acidic and enzymatic conditions.^[6,7]

On the other hand, many functional groups have been replaced with a fluorine atom in view of bioisosterism because many nucleosides fluorinated at their sugar ring such as 2'-F-ddA,^[8] 2'-F-ara-ddC,^[9] and FLT were found to exhibit significant antiviral activities. Furthermore, it is worthy to note that L-nucleoside analogues such as lamivudine can be considered as iso D-nucleoside analogue.

On the basis of these findings, it was interesting to design and synthesize iso D-2',3'-dideoxythianucleoside derivatives with a 3'-fluoro substituent and to evaluate them against various viruses because CH-F group might act as a bioisostere of sugar ring oxygen of lamivudine and/or as a hydrogen bonding acceptor at the active site of their target enzyme, and because the D-sugar skeleton of iso D-2',3'-dideoxythianucleosides resembles L-1,3-oxathiolane ring of lamivudine. Here, we wish to report the asymmetric synthesis and biological activities of novel fluorinated iso D-2',3'-dideoxythianucleosides 1–3.



SCHEME 1 Reagents and conditions: (a) BzCl, DMAP, pyridine, 88°C, 3 hours; (b) BCl₃, CH₂Cl₂, –78°C, 40 minutes; (c) DAST, CH₂Cl₂, –10°C, 30 minutes; (d) 1 M NaOMe, CH₂Cl₂, MeOH, rt, 4 hours; (e) BzOH, PPh₃, DEAD, THF, 60°C, 5 hours; (f) 1 M NaOMe, MeOH, CH₂Cl₂, rt, 7 hours.



SCHEME 2 Reagents and conditions: (a) N^3 -benzoyl uracil or N^3 -benzoyl thymine, PPh₃, DEAD, THF, rt, overnight, 62% for **12**, 66% for **13**; (b) 1 M NaOMe, MeOH, CH₂Cl₂, rt, 6 hours, 82% for **14**, overnight, 94% for **15**; (c) 1 M TBAF, THF, rt, 2 hours, 97% for **1**, 98% for **2**; (d) Ac₂O, pyridine, rt, overnight; (e) i) 1,2,4-triazole, POCl₃, pyridine, rt, overnight; ii) 1,4-dioxane, 28% NH₄OH, rt, overnight; iii) NH₃, MeOH, rt, overnight.

CHEMISTRY

A strategy for the synthesis of glycone of iso-D-2',3'-dideoxy-3'-fluorothianucleosides **1–3** is outlined in Scheme 1. It was envisioned that 1,4-anhydro-4-thioarabitol **5** derived from D-glucose via 1,2;5,6-di-O-isopropylidene-D-glucofuranose (**4**) could be an appropriate intermediate to synthesize D-4-fluorothiophen-3-ol **11**, which could be condensed with pyrimidine bases to afford lamivudine analogs **1–3**.

Diacetone glucose (**4**) was derived from D-glucose by the known one-pot synthesis method reported by Moravcova and his coworkers.^[10] Compound **4** was converted into 1,4-anhydro-4-thioarabitol **5** according to the known procedure developed by Yoshimura and his coworkers over ten steps.^[11] Benzoylation of compound **5** with benzoyl chloride, DMAP and pyridine at elevated temperature (88°C) gave the corresponding benzoate **6** in 94% yield. Debenzylation of **6** with BCl₃ at –78°C gave **7**. Fluorination of **7** with DAST gave the fluorinated compound **8** in 88% yield with the desired “ α ” stereochemistry through double inversion mechanism by the nucleophilic participation of the ring sulfur atom.^[12,13] Removal of benzoyl group of **8** using catalytic amounts of 1 M NaOMe in MeOH gave the corresponding alcohol **9** in nearly quantitative yield, which was used for coupling with benzoic acid under Mitsunobu conditions. During Mitsunobu reaction the nucleophilic participation of sulfur atom occurred only to the extent of 3~5%. The major product **10** which underwent a single inversion was formed in 88% yield with its epimer (3~5%) at 3-position. The structures of major and minor product, **10** and its epimer, were confirmed by comparing ¹H NMR data of the corresponding alcohols generated from each epimers after debenzoylation with those of compound **9**. Debenzoylation of **10** afforded the glycosyl donor **11**.

Synthesis of pyrimidine nucleoside analogs **1–3** is illustrated in Scheme 2. Coupling of **11** with N^3 -benzoyluracil and N^3 -benzoylthymine, PPh₃ and DEAD gave the desired β -nucleosides **12** (62%) and **13** (66%), respectively. It is worthy to note that the participation of sulfur atom did not occur at all during coupling of glycosyl donor **11** with nucleobases. Deprotection

of *N*-benzoyl group with 1 M NaOMe produced TBDPS-protected compounds **14** and **15** in 82% and 94% yield, respectively. Finally, treatment of **14** and **15** with TBAF gave the desired final compounds **1** and **2**, respectively. Compound **1** was converted into lamivudine analog, cytosine nucleoside **3** via acetylation of the hydroxyl group followed by successive three conventional steps (1,2,4-triazole, POCl₃, pyridine; 1,4-dioxane, NH₄OH; NH₃, MeOH)^[14] in overall 54% yield.

BIOLOGICAL RESULTS

Antiviral activities of all iso *D*-2',3'-dideoxy-3'-fluorothianucleoside derivatives **1–3** synthesized as a bioisostere of lamivudine were measured against a variety of viruses such as HIV type 1 and 2, EMCV, Cox. B3, VSV, and HSV type 1 and 2. EC₅₀ of compounds **1** and **2** exceeded 100 µg/mL and also did not show any cytotoxicity up to 100 µg/mL at all tested cells such as MT4, HeLa, and Vero cells. On the other hand, cytosine nucleoside derivative **3** exhibited potent anti-VSV activity (EC₅₀ = 9.43 µg/mL) with high cytotoxicity (CC₅₀ = 14.54 µg/mL) in HeLa cell, but was inactive against the other viruses and not cytotoxic. It is very interesting that cytosine nucleoside analog **3** designed as a bioisostere of lamivudine showed anti-VSV activity instead of the expected anti-HIV activity. It is worthy to note that **3** classified into ddNs exhibited potent anti-VSV activity because VSV belongs to RNA virus.

CONCLUSION

We have designed and synthesized novel iso *D*-2',3'-dideoxythianucleoside derivatives **1–3** as a bioisostere of lamivudine to search for new anti-HIV agents. Among compounds tested, only cytosine analog **3** showed potent anti-VSV activity even if it pertains to ddNs classification and VSV is RNA virus. This observation implies that iso *D*-2',3'-dideoxy sugar templates might act as a sugar surrogate of nucleosides for the development of anti-RNA virus agent. Information about participation of sulfur atom during fluorination reaction using DAST and Mitsunobu reaction will be of great help in synthesizing sulfur-containing compounds.

REFERENCES

1. Furman, P.A.; Fyfe, J.A.; St. Clair, M.H.; Weinhold, K.; Rideout, J.L.; Freeman, G.A.; Lehrman, S.N.; Bolognesi, D.P.; Broder, S.; Mitsuya, H.; Barry, D.W. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. *Proc. Natl. Acad. Sci. USA* **1986**, *83*, 8333–8337.
2. Faulds, D.; Brogden, R.N. Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. *Drugs* **1992**, *44*, 94–116.

3. Whittington, R.; Brogden, R.N. Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). *Drugs* **1992**, 44, 656–683.
4. Baba, M.; Pauwels, R.; Herdewijn, P.; De Clercq, E.; Desmyter, J.; Vandeputte, M. Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. *Biochem. Biophys. Res. Commun.* **1987**, 142, 128–134.
5. Soudeyns, H.; Yao, S.-J.; Gao, W.; Belleau, B.; Kraus, J.-L.; Nguyen-Ba, N.; Spira, B.; Wainberg, M.A. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. *Antimicrob. Agents Chemother.* **1991**, 35, 1386–1390.
6. Bamford, M.J.; Humber, C.C.; Storer, R. Synthesis of (\pm)-2'-oxa-carbocyclic-2',3'-dideoxynucleosides as potential anti-HIV agents. *Tetrahedron Lett.* **1991**, 32, 271–274.
7. Sells, T.B.; Nair, V. Synthetic approaches to novel isomeric dideoxynucleosides containing a chiral furanethanol carbohydrate moiety. *Tetrahedron Lett.* **1993**, 34, 3527–3530.
8. Marquez, V.E.; Tseng, C.K.-H.; Kelley, J.A.; Mitsuya, H.; Broder, S.; Roth, J.S.; Driscoll, J.S. 2',3'-Dideoxy-2'-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV). *Biochem. Pharmacol.* **1987**, 36, 2719–2722.
9. Martin, J.A.; Bushnell, D.J.; Duncan, I.B.; Dunsdon, S.J.; Hall, M.J.; Machin, P.J.; Merrett, J.H.; Parkes K.E.B.; Roberts, N.A.; Thomas, G.J.; Galpin, S.A.; Kinchington, D. Synthesis and antiviral activity of monofluoro and difluoro analogs of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1). *J. Med. Chem.* **1990**, 33, 2137–2145.
10. Moravcova, J.; Capkova, J.; Stanek, J. One-pot synthesis of 1,2-O-isopropylidene- α -xylofuranose. *Carbohydr. Res.* **1994**, 263, 61–66.
11. Yoshimura, Y.; Kitano, K.; Yamada, K.; Satoh, H.; Watanabe, M.; Miura, S.; Sakata, S.; Sasaki, T.; Matsuda, A. A novel synthesis of 2'-modified 2'-deoxy-4'-thiocytidines from D-glucose. *J. Org. Chem.* **1997**, 62, 3140–3152.
12. Jeong, L.S.; Moon, H.R.; Yoo, S.J.; Lee, S.N.; Chun, M.W.; Lim, Y.-H. Ring contraction and rearrangement of 4-thiofuranose derivatives observed during DAST fluorination in the synthesis of L-2'-"up"-fluoro-4'-thiothymidine. *Tetrahedron Lett.* **1998**, 39, 5201–5204.
13. Jeong, L.S.; Yoo, S.J.; Moon, H.R.; Kim, Y.H.; Chun, M.W. Participation of sulfur occurred during the Mitsunobu reaction: synthesis of novel isodideoxythionucleosides. *J. Chem. Soc., Perkin Trans. 1* **1998**, 3325–3326.
14. Shi, J.; Du, J.; Ma, T.; Pankiewicz, K.W.; Patterson, S.E.; Tharnish, P.M.; McBrayer, T.R.; Stuyver, L.J.; Otto, M.J.; Chu, C.K.; Schinazi, R.F.; Watanabe, K.A. Synthesis and anti-viral activity of a series of D- and L-2'-deoxy-2'-fluororibonucleosides in the subgenomic HCV replicon system. *Bioorg. Med. Chem.* **2005**, 13, 1641–1652.